{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:03:13Z","timestamp":1759089793281},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,7,15]]},"DOI":"10.2169\/internalmedicine.9513-22","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T22:23:43Z","timestamp":1657837423000},"page":"2215-2219","source":"Crossref","is-referenced-by-count":5,"title":["Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient"],"prefix":"10.2169","volume":"61","author":[{"given":"Masao","family":"Hagihara","sequence":"first","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Uchida","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Ohara","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morihiro","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Hematology, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomiyuki","family":"Sugi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiko","family":"Mitamura","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Eiju General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Pagano L, Salmanton-Garcia J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol 14: 168, 2021."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hagihara M, Ohara S, Uchida T, Inoue M. Practical management of patients with hematological diseases during the COVID-19 pandemic in Japan. Int J Hematol 114: 709-718, 2021.","DOI":"10.1007\/s12185-021-03175-x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Thakkar A, Pradhan K, Jindal S, et al. Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anticancer therapy. Nat Cancer 2: 392-399, 2021.","DOI":"10.1038\/s43018-021-00191-y"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. Cell 183: 1901-1912 e9, 2020.","DOI":"10.1016\/j.cell.2020.10.049"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Tepasse PR, Hafezi W, Lutz M, et al. Persisting SARS-CoV-2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature. Br J Haematol 190: 185-188, 2020.","DOI":"10.1111\/bjh.16896"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Koff AG, Laurent-Rolle M, Hsu JC, Malinis M. Prolonged incubation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a patient on rituximab therapy. Infect Control Hosp Epidemiol 42: 1286-1288, 2021.","DOI":"10.1017\/ice.2020.1239"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Helleberg M, Niemann CU, Moestrup KS, et al. Persistent COVID-19 in an immunocompromised patient temporarily responsive to two courses of remdesivir therapy. J Infect Dis 222: 1103-1107, 2020.","DOI":"10.1093\/infdis\/jiaa446"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. N Engl J Med 383: 2291-2293, 2020.","DOI":"10.1056\/NEJMc2031364"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Nakajima Y, Ogai A, Furukawa K, et al. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother 27: 387-389, 2021.","DOI":"10.1016\/j.jiac.2020.12.001"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Aydillo T, Gonzalez-Reiche AS, Aslam S, et al. Shedding of viable SARS-CoV-2 after immunosuppressive therapy for cancer. N Engl J Med 383: 2586-2588, 2020.","DOI":"10.1056\/NEJMc2031670"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Yasuda H, Tsukune Y, Watanabe N, et al. Persistent COVID-19 pneumonia and failure to develop anti-SARS-CoV-2 antibodies during rituximab maintenance therapy for follicular lymphoma. Clin Lymphoma Myeloma Leuk 20: 774-776, 2020.","DOI":"10.1016\/j.clml.2020.08.017"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Houot R, Levy R, Cartron G, Armand P. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? Eur J Cancer 136: 4-6, 2020.","DOI":"10.1016\/j.ejca.2020.06.017"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33: 388-396, 2013.","DOI":"10.1007\/s10875-012-9813-x"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood 122: 1946-1953, 2013.","DOI":"10.1182\/blood-2013-04-494096"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Maneikis K, Sablauskas K, Ringeleviciute U, et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Lancet Haematol 8: e583-e592, 2021.","DOI":"10.1016\/S2352-3026(21)00169-1"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Levavi H, Lancman G, Gabrilove J. Impact of rituximab on COVID-19 outcomes. Ann Hematol 100: 2805-2812, 2021.","DOI":"10.1007\/s00277-021-04662-1"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Yamayoshi S, Sakai-Tagawa Y, Koga M, et al. Comparison of rapid antigen tests for COVID-19. Viruses 12: 1420, 2020.","DOI":"10.3390\/v12121420"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis 68: 247-255, 2019.","DOI":"10.1093\/cid\/ciy458"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Saito H, Maruyama D, Maeshima AM, et al. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma. Blood Cancer J 5: e362, 2015.","DOI":"10.1038\/bcj.2015.86"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Keller MD, Harris KM, Jensen-Wachspress MA, et al. SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein. Blood 136: 2905-2917, 2020.","DOI":"10.1182\/blood.2020008488"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Gallais F, Velay A, Nazon C, et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. Emerg Infect Dis 27: 113-121, 2021.","DOI":"10.3201\/eid2701.203611"},{"key":"22","unstructured":"22. Bange EM, Han NA, Wileyto P, et al. CD8<sup>+<\/sup> T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med 27: 1280-1289, 2021."},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Sahin U, Muik A, Derhovanessian E, et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses. Nature 586: 594-599, 2020.","DOI":"10.1038\/s41586-020-2814-7"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Soy M, Atagunduz P, Atagunduz I, Sucak GT. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic. Rheumatol Int 41: 7-18, 2021.","DOI":"10.1007\/s00296-020-04636-y"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sung A, Bailey AL, Stewart HB, et al. Isolation of SARS-CoV-2 in viral cell culture in immunocompromised patients with persistently positive RT-PCR results. Front Cell Infect Microbiol 12: 804175, 2022.","DOI":"10.3389\/fcimb.2022.804175"},{"key":"26","unstructured":"26. Arai T, Mukai S, Kazama R, et al. Persistent viral shedding of severe acute respiratory syndrome coronavirus 2 after treatment with bendamustine and rituximab: a case report. J Infect Chemother. Forthcoming."},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Regalado-Artamendi I, Jimenez-Ubieto A, Hernandez-Rivas JA, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hemasphere 5: e538, 2021.","DOI":"10.1097\/HS9.0000000000000538"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Sepulcri C, Dentone C, Mikulska M, et al. The longest persistence of viable SARS-CoV-2 with recurrence of viremia and relapsing symptomatic COVID-19 in an immunocompromised patient - a case study. Open Forum Infect Dis 8: ofab217, 2021.","DOI":"10.1093\/ofid\/ofab217"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/14\/61_9513-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T04:21:54Z","timestamp":1657945314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/14\/61_9513-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,15]]},"references-count":28,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9513-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,15]]},"article-number":"9513-22"}}